Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation shows strong program spending and asset growth, with fluctuating annual revenues and expenses.
EIN: 201082179 · New York, NY · NTEE: V36 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $56.4M |
| Total Expenses | $61.9M |
| Program Spending | 85% |
| Net Assets | $260.0M |
| Transparency Score | 90/100 |
Search Intent Cockpit
Alzheimers Drug Discovery Foundation Form 990, Revenue, CEO Pay, and IRS Filing Signals
Alzheimers Drug Discovery Foundation is surfaced here as a decision-ready nonprofit financial profile, not just a charity listing. The page consolidates IRS Form 990 revenue, expenses, assets, tax-exempt classification, executive compensation, mission score, red flags, and year-by-year filing history so donors, researchers, journalists, and grant teams can answer the common search questions around Alzheimers Drug Discovery Foundation in one place.
Form 990 Filing Summary
13 filing years are available, with latest revenue of $37.7M and expenses of $61.9M.
Revenue and Expenses
Alzheimers Drug Discovery Foundation reported $37.7M in revenue and $61.9M in expenses, a deficit of $24.2M.
Executive Compensation
Officer, director, trustee, and key employee pay is reviewed from IRS 990 compensation disclosures when present.
Charity Score and Red Flags
90/100 mission score, 2 red flags, and 4 strengths are shown from structured and AI review.
Is Alzheimers Drug Discovery Foundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
IRS 990 Data Cockpit
Where the Money Comes From and Where It Goes
Revenue Source Mix
Revenue-source line items are not available on the stored filing yet. Future ingestion now preserves contribution, program-revenue, and investment-income fields when ProPublica provides them.
Expense Deployment
| Program services | $52.7M (85%) |
Across stored filings, Alzheimers Drug Discovery Foundation shows contribution history pending. Next enrichment targets: revenue-source fields, IRS BMF classification.
Decision Cockpit
One-Stop Donor, Research, and Peer Context Hub
| Decision Lens | Signal | What to Inspect Next |
|---|---|---|
| Legitimacy | Some Concerns | Good filing record; 2 red flags identified |
| Mission spend | 85% to programs | Excellent |
| Financial durability | Grade B | 13 stored filing years |
| Peer context | Compare with Healthy Capital District Initiative | New York and Category V context |
Trust Check
Review legitimacy, deductibility, red flags, and filing consistency.
Open charity check →Peer Benchmark
Compare against real state and category peers.
Compare with Healthy Capital District Initiative →All New York nonprofits
All Category V
Local and Sector Spokes
Move into this nonprofit's local market, category, and sector maps.
New York, NY nonprofitsCategory V in New York
Public Benefit in New York
Follow the Money
Jump into spending, compensation, rankings, and filing-year evidence.
State spending analysisState compensation analysis
Category V spending
Best Category V charities in New York
Relevant rankings
Donation Decision Flow
From Trust Check to Better Alternatives
Alternative Shopping
Similar Nonprofits Donors Should Compare
Skowhegan School Of Painting And Sculpture Inc
New York, NY · $20.8M revenue · Score 90/100
Compare side-by-sideGarrison Institute
Garrison, NY · $4.1M revenue · Score 90/100
Compare side-by-sideGreater Rochester Enterprise Foundation Inc
Rochester, NY · $2.0M revenue · Score 90/100
Compare side-by-sideGreater Rochester Enterprise Inc
Rochester, NY · $2.3M revenue · Score 88/100
Compare side-by-sideNext Best Actions
Keep the Investigation Moving
Alzheimers Drug Discovery Foundation directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation (EIN: 201082179) is a nonprofit organization based in New York, NY, classified under NTEE code V36. The organization reported total revenue of $56.4M and total assets of $299.4M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alzheimers Drug Discovery Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Alzheimers Drug Discovery Foundation is a major nonprofit that has been operating for 21 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 13.7%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $37.7M |
| Total Expenses | $61.9M |
| Surplus / Deficit | $-24,201,568 |
| Total Assets | $324.2M |
| Total Liabilities | $64.2M |
| Net Assets | $260.0M |
| Operating Margin | -64.1% |
| Debt-to-Asset Ratio | 19.8% |
| Months of Reserves | 62.8 months |
Financial Health Grade: B
In 2023, Alzheimers Drug Discovery Foundation reported a deficit of $24.2M with expenses exceeding revenue, holds 62.8 months of operating reserves (strong position), has a debt-to-asset ratio of 19.8% (very low leverage).
Financial Trends
Over 13 years of filings (2011–2023), Alzheimers Drug Discovery Foundation's revenue has grown at a compound annual growth rate (CAGR) of 13.7%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -85.1% | +68.1% | -4.7% |
| 2022 | +379.0% | -0.8% | +192.3% |
| 2021 | +91.9% | +31.4% | +19.6% |
| 2020 | +21.7% | -12.9% | +0.2% |
| 2019 | -59.3% | +100.3% | +7.9% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2005 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Alzheimers Drug Discovery Foundation with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Alzheimers Drug Discovery Foundation allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $24.2M, with expenses exceeding revenue.
- Debt-to-asset ratio: 19.8%.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size and financial activity. This suggests that executive leadership may be compensated through other means, or that the organization operates with a unique compensation structure where officers are not directly paid from the organization's funds, which would be a significant positive for resource allocation.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Alzheimers Drug Discovery Foundation's IRS 990 filings:
- Inconsistent revenue generation, with significant fluctuations year-over-year (e.g., $254M in 2022 vs. $37.7M in 2023).
- Expenses exceeding revenue in multiple periods (e.g., 2023, 2019, 2017), indicating reliance on reserves or investment income.
Strengths
The following positive indicators were identified for Alzheimers Drug Discovery Foundation:
- Strong program spending ratio, with 85% of expenses dedicated to programs in 2023.
- Significant and consistent growth in assets, from $19.3M in 2014 to $324.1M in 2023, indicating robust financial health.
- Consistent reporting of 0% officer compensation across all filings, suggesting efficient use of funds or unique compensation structure.
- Substantial financial reserves, with assets significantly outweighing liabilities (e.g., $324.1M assets vs. $64.1M liabilities in 2023).
Frequently Asked Questions about Alzheimers Drug Discovery Foundation
Is Alzheimers Drug Discovery Foundation a legitimate charity?
Alzheimers Drug Discovery Foundation (EIN: 201082179) is a registered tax-exempt nonprofit based in New York. Our AI analysis gives it a Mission Score of 90/100. It has 13 years of IRS 990 filings on record. Total revenue: $56.4M. 2 red flags identified. 4 strengths noted. Financial health grade: B.
How does Alzheimers Drug Discovery Foundation spend its money?
Alzheimers Drug Discovery Foundation directs 85% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Alzheimers Drug Discovery Foundation tax-deductible?
Alzheimers Drug Discovery Foundation is registered as a tax-exempt nonprofit (EIN: 201082179). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What percentage of Alzheimers Drug Discovery Foundation's spending goes to programs?
Alzheimers Drug Discovery Foundation directs 85% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Alzheimers Drug Discovery Foundation compare to similar nonprofits?
With a transparency score of 90/100 (Excellent), Alzheimers Drug Discovery Foundation is above average for NTEE category V36 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Alzheimers Drug Discovery Foundation located?
Alzheimers Drug Discovery Foundation is headquartered in New York, New York and files with the IRS under EIN 201082179. It is classified under NTEE code V36.
How many years of IRS 990 filings does Alzheimers Drug Discovery Foundation have?
Alzheimers Drug Discovery Foundation has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $56.4M in total revenue.
Is the Alzheimers Drug Discovery Foundation a good charity?
Based on the provided data, ADDF appears to be a good charity. It consistently allocates a high percentage of its expenses to program services (e.g., 85% in 2023), has shown significant asset growth, and reports 0% officer compensation, indicating a strong focus on its mission and efficient use of funds.
How does ADDF manage its expenses when revenue is lower?
In years where expenses exceed revenue (e.g., 2023 with $61.9M expenses vs. $37.7M revenue, or 2019 with $32.4M expenses vs. $22.7M revenue), ADDF likely draws upon its substantial accumulated assets and prior year surpluses to cover operational costs. The organization's assets grew from $19.3M in 2014 to $324.1M in 2023, providing a significant financial cushion.
What caused the large revenue spike in 2022?
The revenue spike to $254,027,105 in 2022 is a significant outlier compared to other years. While the specific cause isn't detailed in the provided data, it could be attributed to a major one-time donation, a large grant, or a highly successful fundraising campaign during that period.
Filing History
IRS 990 filing history for Alzheimers Drug Discovery Foundation showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Alzheimers Drug Discovery Foundation's revenue has grown by 368.7%, moving from $8.1M to $37.7M. Total assets increased by 4106.1% over the same period, from $7.7M to $324.2M. Total functional expenses rose by 975.1%, from $5.8M to $61.9M. In its most recent filing year (2023), Alzheimers Drug Discovery Foundation reported a deficit of $24.2M, with expenses exceeding revenue. The organization holds $64.2M in liabilities against $324.2M in assets (debt-to-asset ratio: 19.8%), resulting in net assets of $260.0M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $37.7M | $61.9M | $324.2M | $64.2M | — | — |
| 2022 | $254.0M | $36.8M | $340.3M | $56.7M | — | View 990 |
| 2021 | $53.0M | $37.1M | $116.4M | $52.4M | — | View 990 |
| 2020 | $27.6M | $28.3M | $97.4M | $48.1M | — | View 990 |
| 2019 | $22.7M | $32.4M | $97.2M | $47.0M | — | View 990 |
| 2018 | $55.8M | $16.2M | $90.0M | $30.1M | — | View 990 |
| 2017 | $14.5M | $17.8M | $46.0M | $25.7M | — | View 990 |
| 2016 | $23.1M | $17.0M | $45.4M | $21.8M | — | View 990 |
| 2015 | $22.3M | $13.1M | $31.1M | $13.6M | — | View 990 |
| 2014 | $12.0M | $10.0M | $19.3M | $10.8M | — | View 990 |
| 2013 | $9.3M | $7.7M | $14.7M | $8.2M | — | View 990 |
| 2012 | $9.7M | $7.8M | $12.6M | $7.7M | — | View 990 |
| 2011 | $8.1M | $5.8M | $7.7M | $4.6M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $37.7M, expenses of $61.9M, and assets of $324.2M (revenue -85.1% year-over-year).
- 2022: Revenue of $254.0M, expenses of $36.8M, and assets of $340.3M (revenue +379.0% year-over-year).
- 2021: Revenue of $53.0M, expenses of $37.1M, and assets of $116.4M (revenue +91.9% year-over-year).
- 2020: Revenue of $27.6M, expenses of $28.3M, and assets of $97.4M (revenue +21.7% year-over-year).
- 2019: Revenue of $22.7M, expenses of $32.4M, and assets of $97.2M (revenue -59.3% year-over-year).
- 2018: Revenue of $55.8M, expenses of $16.2M, and assets of $90.0M (revenue +285.5% year-over-year).
- 2017: Revenue of $14.5M, expenses of $17.8M, and assets of $46.0M (revenue -37.2% year-over-year).
- 2016: Revenue of $23.1M, expenses of $17.0M, and assets of $45.4M (revenue +3.2% year-over-year).
- 2015: Revenue of $22.3M, expenses of $13.1M, and assets of $31.1M (revenue +86.7% year-over-year).
- 2014: Revenue of $12.0M, expenses of $10.0M, and assets of $19.3M (revenue +28.8% year-over-year).
- 2013: Revenue of $9.3M, expenses of $7.7M, and assets of $14.7M (revenue -3.7% year-over-year).
- 2012: Revenue of $9.7M, expenses of $7.8M, and assets of $12.6M (revenue +19.9% year-over-year).
- 2011: Revenue of $8.1M, expenses of $5.8M, and assets of $7.7M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Alzheimers Drug Discovery Foundation:
Data Sources and Methodology
This transparency report for Alzheimers Drug Discovery Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.